14th Drug Discovery for Neurodegeneration Workshop

A Virtual Course on Translating Research into Novel Drug Targets


Virtual, April 26-28, 2020

UPDATE CONCERNING COVID-19 (NOVEL CORONAVIRUS)

As the COVID-19 situation continues to evolve and impact people and communities globally, the ADDF’s top priority is to ensure the safety, health, and well-being of our supporters, partners, and the ADDF community. For that reason, the 14th Annual Drug Discovery for Neurodegeneration Workshop will be held as a virtual meeting.

In place of the in-person event, we are now planning to host the meeting online with virtual presentations and opportunities to interact with each other through an online platform. We’ll share additional details on our plans in the coming weeks.

These decisions are not easy to make but we thank everyone involved for their flexibility and support.

We look forward to a great workshop!

This interactive workshop is designed as an introductory course covering all aspects of drug discovery for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s disease, Amyotrophic Lateral Sclerosis, Frontotemporal Degeneration, and Multiple Sclerosis.

Delegates are drawn from academia, industry, associations/societies, government and media.  The event attracts about 150-170 attendees allowing for a higher degree of interactivity and networking.

  • Academia 47% 47%
  • Industry 33% 33%
  • Non-profit 13% 13%
  • Government 3% 3%
  • Consulting 3% 3%
  • Other 1% 1%

%

Percentage of attendees selecting quality of the meeting as "Excellent" and "Very Good"

OBJECTIVES

  • Train a cadre of interdisciplinary scientists in the principles of drug discovery for neurodegenerative disease.
  • Provide a platform to exchange ideas, knowledge and resources about drug discovery for neurodegenerative disease.
  • Stimulate pre-clinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of neurodegenerative disease.
  • Build public-private partnerships that will accelerate drug discovery for neurodegenerative disease.

BENEFITS FOR PARTICIPANTS

  • Gain an understanding of the drug discovery pipeline, from target identification to clinical trials
  • Learn from case studies and challenges associated with developing drugs for neurodegenerative diseases
  • Attend panel discussions to learn about careers outside academia
  • Attend panel discussions to learn about relevant grant opportunities and how to get funded
  • Present your poster

SPEAKERS and CHAIRS

Joseph Araujo
InterVivo Solutions

Kurt Brunden
Univ. of Pennsylvania

Charles Cywin
NIH/NINDS

Kuldip Dave
The ALS Assoc.

Philip De Jager
Columbia Univ.

Anita DiFrancesco
Samumed

Maria Emanuel
Univ. of NH

Jacques Galipeau
Univ. of Wisconsin

John Gerdes
Rio Pharma

Edmund Graziani
Apertor Labs

David Kemp
Cure PSP

James Kirkland
Mayo Clinic

Walter Kostich
Natl. MS Society

Douglas Macdonald
CHDI Foundation

Zane Martin
NIH/NIA

Liliana Menalled
MJFF

Kenneth Olivier
Biotech Primer

Natasha Penner
Biogen

Allen Reitz
ALS Biopharma

Edward Spack
Vector BioSol./Therini

Nadine Tatton
The AFTD

Leticia Toledo-Sherman
Rainwater Fdtion

Ishu Venkataraman
Euroimmun

D. Martin Watterson
Northwestern Univ.

Maurice Zauderer
Vaccinex

SPONSORS